ZyVersa Therapeutics EBIT

As of the most recent data (March 2026), ZVSA shows a EBIT of $-25B. That compares with $-4.4B in the prior-year period — down 458.0% year over year. That is below the sector sector average of $-26M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZVSA's EBIT is now $-25B (was $-4.4B) — a 458.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ZyVersa Therapeutics is outperforming or lagging.

The its sector sector average EBIT is about $-26M. ZyVersa Therapeutics is at $-25B, which is lower that average. That is roughly 95156.0% below the sector mean. Use the comparison chart on this page to see how ZVSA stacks up against individual peers as well.

Tracking ZVSA's ebit over time shows whether ZyVersa Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-25B That compares with $-4.4B in the prior-year period — down 458.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has ZyVersa Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-25B) with ownership activity and broader fundamentals.